Cripe LD - Search Results

1

Role for c-jun N-terminal kinase in treatment-refractory acute myeloid leukemia (AML): signaling to multidrug-efflux and hyperproliferation.

Cripe LD, Gelfanov VM, Smith EA, Spigel DR, Phillips CA, Gabig TG, Jung SH, Fyffe J, Hartman AD, Kneebone P, Mercola D, Burgess GS, Boswell HS. Cripe LD, et al. Leukemia. 2002 May;16(5):799-812. doi: 10.1038/sj.leu.2402457. Leukemia. 2002. PMID: 11986940

2

Adult acute leukemia.

Cripe LD. Cripe LD. Curr Probl Cancer. 1997 Jan-Feb;21(1):1-64. doi: 10.1016/s0147-0272(97)80006-2. Curr Probl Cancer. 1997. PMID: 9058027 Review.

3

Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase.

Burgess GS, Williamson EA, Cripe LD, Litz-Jackson S, Bhatt JA, Stanley K, Stewart MJ, Kraft AS, Nakshatri H, Boswell HS. Burgess GS, et al. Among authors: cripe ld. Blood. 1998 Oct 1;92(7):2450-60. Blood. 1998. PMID: 9746785 Free article.

4

Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995.

Gordon MS, Young ML, Tallman MS, Cripe LD, Bennett JM, Paietta E, Longo W, Gerad H, Mazza J, Rowe JM. Gordon MS, et al. Among authors: cripe ld. Leuk Res. 2000 Oct;24(10):871-5. doi: 10.1016/s0145-2126(00)00043-6. Leuk Res. 2000. PMID: 10996206 Clinical Trial.

5

Acute myeloid leukemia in adults.

Cripe LD, Hinton S. Cripe LD, et al. Curr Treat Options Oncol. 2000 Apr;1(1):9-17. doi: 10.1007/s11864-000-0011-3. Curr Treat Options Oncol. 2000. PMID: 12057057 Review.

6

Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trials.

Paietta E, Neuberg D, Bennett JM, Dewald G, Rowe JM, Cassileth PA, Cripe L, Tallman MS, Wiernik PH; Eastern Cooperative Oncology Group. Paietta E, et al. Leukemia. 2003 Aug;17(8):1544-50. doi: 10.1038/sj.leu.2402999. Leukemia. 2003. PMID: 12886241

7

Phase II study of low-dose topotecan in myelodysplastic syndromes: a Hoosier Oncology Group (HOG) study.

Vaena DA, Walker P, Pennington K, Stephens A, Stender MJ, Yiannoutsos CT, Young C, Stoner C, Cripe LD; Hoosier Oncology Group. Vaena DA, et al. Among authors: cripe ld. Leuk Res. 2004 Jan;28(1):49-52. doi: 10.1016/s0145-2126(03)00181-4. Leuk Res. 2004. PMID: 14630080 Clinical Trial.

8

12-O-Tetradecanoylphorbol-13-acetate in acute myeloid leukemia.

Chan RJ, Cripe LD. Chan RJ, et al. Among authors: cripe ld. Leuk Res. 2005 Oct;29(10):1107-8. doi: 10.1016/j.leukres.2005.04.015. Leuk Res. 2005. PMID: 15913776 No abstract available.

9

Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997.

Cripe LD, Rader K, Tallman MS, Gordon MS, Paietta E, Bennett J, Neuberg D, Litzow MR, O'brien TE, Rowe JM. Cripe LD, et al. Leuk Res. 2006 Jul;30(7):823-7. doi: 10.1016/j.leukres.2005.11.006. Epub 2006 Jan 18. Leuk Res. 2006. PMID: 16413056 Clinical Trial.

10

Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.

Hartman AD, Wilson-Weekes A, Suvannasankha A, Burgess GS, Phillips CA, Hincher KJ, Cripe LD, Boswell HS. Hartman AD, et al. Among authors: cripe ld. Exp Hematol. 2006 Oct;34(10):1360-76. doi: 10.1016/j.exphem.2006.05.019. Exp Hematol. 2006. PMID: 16982329 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

95 results

Search Page

Filters